Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for AVITA Medical (RCEL) over the last 7 years, with Q4 2025 value amounting to $7.4 million.

  • AVITA Medical's Change in Accured Expenses rose 60553.28% to $7.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.7 million, marking a year-over-year increase of 70735.29%. This contributed to the annual value of $2.7 million for FY2025, which is 70735.29% up from last year.
  • According to the latest figures from Q4 2025, AVITA Medical's Change in Accured Expenses is $7.4 million, which was up 60553.28% from -$2.1 million recorded in Q3 2025.
  • AVITA Medical's Change in Accured Expenses' 5-year high stood at $7.4 million during Q4 2025, with a 5-year trough of -$4.8 million in Q2 2025.
  • For the 5-year period, AVITA Medical's Change in Accured Expenses averaged around -$38055.6, with its median value being -$599000.0 (2021).
  • In the last 5 years, AVITA Medical's Change in Accured Expenses surged by 78213.63% in 2023 and then crashed by 73020.83% in 2025.
  • Over the past 5 years, AVITA Medical's Change in Accured Expenses (Quarter) stood at -$655000.0 in 2021, then skyrocketed by 167.63% to $443000.0 in 2022, then surged by 143.12% to $1.1 million in 2023, then crashed by 235.93% to -$1.5 million in 2024, then surged by 605.53% to $7.4 million in 2025.
  • Its Change in Accured Expenses stands at $7.4 million for Q4 2025, versus -$2.1 million for Q3 2025 and -$4.8 million for Q2 2025.